Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXSCEL cardiovascular outcomes trial of once-weekly exenatide in type 2 diabetes
NL-OMON41366Phase 3Active, not recruiting
- Sponsor
- Amylin Pharmaceuticals
- Start
- Aug 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Bydureon plus usual care with Placebo plus usual care (2 arms). Primary endpoint: Time to first confirmed cardiovascular event in the primary composite endpoint. Started Aug 2014; status: active, not recruiting.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON41366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41366.